Latest news with #Dasatinib
Mint
20-06-2025
- Business
- Mint
Stocks to trade today: Trade Brains Portal recommends two stocks for 20 June
Today, we recommend two stocks, one from the healthcare sector and the other from the railways sector. We also analyze the market's performance on Thursday to understand what may lie ahead for the stock indices in the coming days. Here are two stocks to trade today, as recommended by Trade Brains Portal Biocon Ltd (Current price: ₹349) Target price: ₹405 in 16-24 months Stop loss: ₹320 Why it's recommended: Founded in 1978, Biocon Ltd is the top biopharma firm in India, improving the lives of people in more than 120 countries by developing novel and cost-effective treatments for cancer, diabetes, and autoimmune diseases. The company employs more than 18,200 people who work in the research services, biosimilars, generics, and new biologics divisions. The largest integrated insulin manufacturing and research and development facility in Malaysia is operated by Biocon, which also contains one of the biggest biomanufacturing facilities for insulin, monoclonal antibodies, and devices. The group's four incubated businesses are Biocon Biologics, which focuses on biosimilars and accounts for 58% of total revenue in FY25; the generics division, which contributes 19%; and Syngene, which provides research services and accounts for 23% of total revenue in FY25. When comparing the performance on a like-for-like basis, revenue from operations totalled ₹15,262 crore, a 10% year-on-year increase; Ebitda reached ₹4,374 crore with a margin of 27%, and the net profit in FY25 was ₹1,013 crore, which represents a significant turnaround. The company has launched several new products, such as Liraglutide in the UK, Dasatinib in the US, and YesintekTM, which boosted revenue performance in Q4FY25. Going forward, the company plans to invest $200-250 million in capital expenditures across several business segments. While Syngene will increase the capacity of its research centres and production facilities for large and small compounds, BBL wants to expand its insulin factory in Malaysia as part of its capital expenditure plans. It is anticipated to spend $50 million in capital expenditures on generics in the upcoming year. The business anticipates approving generic Copaxone in the US and launching liraglutide there. According to management, Lenalidomide will be introduced in limitless quantities, with more launches scheduled for FY26. Additionally, five other products—Stelara, Bevacizumab, Aspart, Aflibercept, and Denosumab—will be introduced during the next 12 to 18 months. Risk Factor: If clearances from the US Food and Drug Administration, the European Medicines Agency, and those in the Asian and Latin American markets are delayed, their biosimilar business may miss out on opportunities. Additionally, the company faces fierce competition from a number of cost-competitive Indian enterprises as well as strong defense tactics from innovative companies that produce authorized generics. Also Read: Is the Israel-Iran war a billion-dollar threat to Adani Ports & SEZ? Titagarh Rail Systems Ltd (Current price: ₹839) Target price: ₹1,050 in 16-24 months Stop loss: ₹730 Why it's recommended: Titagarh Rail Systems was founded in 1997 and has over 25 years of expertise as a top provider of comprehensive mobility solutions in India. Its main activities include the production of passenger coaches, propulsion equipment, urban metros, semi-high-speed trains, and a variety of wagons, including specialized ones. With four production sites, the firm can now produce 12,000 wagons and 300 coaches annually, processing about 30,000 tonnes of casting steel. As of FY25, their entire order book was worth ₹11,200 crore. Titagarh Rail Systems is the only Indian company that produces both wagons and coaches. In FY25, operational revenue was ₹3,867 crore, a slight increase over ₹3,853 crore in FY24; however, it increased 18% CAGR since FY23. PAT stood at ₹274 crore, down 4.9% from ₹288 crore in FY24; however, it has been increasing at a robust CAGR of 43% since FY23. In FY25, the FRS segment's revenue was ₹3,610.27 crore, up 5.64% year over year. In FY25, the PRS segment's income was ₹255.55 crore. The company achieved a record for the most wagons ever produced in a single year in India, with 9,431 wagons. In FY25, it produced 27,240 metric tonnes in the foundry, setting a new production record. In order to increase its production to a significantly higher level in FY26, the company plans to expand its foundry by constructing fully modern foundry production facilities. About 40,000 tonnes of castings are what the company hopes to produce in the first phase of production in FY26. Since the supply chain problems with China have been fixed, the business anticipates that manufacturing for the Bangalore Metro will be rather streamlined. It is anticipated that production will be completely simplified starting in Q2 of FY26. Starting in FY26, the company plans to increase its propulsion division by between 125 and 150 traction motors every month, or 1,500 to 1,800 traction motors per month. The company has its sights set on winning a number of projects from the enormous potential pipeline. Among the major projects are the anticipated ₹15,800 crore Metro coach contracts and the ₹72,000 crore Vande Bharat Coach. Also Read: Is India's premium at risk? As Israel-Iran conflict sparks FPI outflows, valuation debate rages Risk Factor: More than 90% of the company's operating revenues come from freight rail systems and wagons, and Indian Railways continues to be the company's biggest source of sales. Additionally, geographically speaking, the company works on nearly all local projects and has little to no exposure to international enterprises. Market recap As the benchmark indices were flat amid the ongoing geopolitical worries that continued to worry investors, who remained vigilant, the Indian markets stayed flat and followed a bearish trend throughout the market hours on Thursday. The Nifty 50 hit an intraday low of 24,733.40 after opening at 24,803.25. Similar to this, the BSE Sensex opened at 81,403.94 and fell as low as 81,191.04 during the day. With an RSI of 51.65, the Nifty 50 closed at 24,793.25, down -18.80 points, or -0.08%, and fell below the 20-day EMA but above the 50/100/200 throughout the day. In contrast, the BSE Sensex closed below the 20-day EMA but above the 50/100/200 in the daily time frame at 81,361.87, down -82.79 points, or -0.10%, with an RSI of 50.50. The majority of sectoral indices ended in the red. One of the major losers was the Nifty PSU Bank Index, which ended the day at 6,734.30, down -140.35 points, or -2.04%. For three straight trading sessions, it saw a decrease. Additionally, it was touching the 50-day EMA and trading below the 20-day EMA. Almost all the companies declined in this index, with the Central Bank of India, Bank of India, Punjab & Sind Bank, UCO Bank, and Indian Overseas Bank among the major losers, dropping below 3% and causing the index to decline. Amid ongoing tensions between Israel and Iran, Asian markets likewise mirrored the pessimistic outlook on Thursday. For the fourth day in a row, the US Federal Reserve held the fed rate steady while cautioning that Donald Trump's trade policies would increase the danger of inflation. Hong Kong's Hang Seng index closed at 23,237.74, down -1.99%, or -472.95 points. The Nikkei 225 in Japan closed at 38,488.34, down -396.81 points, or -1.02%. At 10,051.97, the Shenzhen Index decreased -123.62 points, or -1.22%. The Shanghai index of China has likewise dropped, closing at 3,362.11, down -26.70 points, or -0.79%. The Kospi index for South Korea, meanwhile, increased slightly, ending at 2,977.74 after rising 0.19%, or 5.55 points. On Thursday, Dow Jones Futures in the US fell -173.60 points, or -0.42%, to 41,996. Also Read: Dull summer casts a cloud on Voltas's air conditioner volumes in Q1 Trade Brains Portal is a stock analysis platform. Its trade name is Dailyraven Technologies Pvt. Ltd, and its Sebi-registered research analyst registration number is INH000015729. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
&w=3840&q=100)
Business Standard
08-05-2025
- Business
- Business Standard
Biocon Q4FY25 results: Consolidated net profit rises 153% to ₹344 crore
Bengaluru-based biopharma major Biocon on Thursday reported a 153 per cent year-on-year (YoY) rise in consolidated net profit to ₹344 crore for the fourth quarter of FY25, compared to ₹ 136 crore in Q4 FY24. The company's profit before tax (PBT) stood at ₹487 crore, up 53 per cent YoY. The Board has also approved a plan to raise up to ₹4,500 crore through various modes, including qualified institutional placement, rights issue, or other permissible routes. The growth was attributed to robust performance across the company's generics, biologics, and research services businesses. Biocon's total consolidated revenue for Q4 FY25 was ₹4,454 crore, up from ₹ 3,966 crore in Q4 FY24. EBITDA stood at ₹1,115 crore, marking a 16 per cent rise, with a maintained margin of 25 per cent. For the full financial year FY25, revenue from operations grew 9 per cent to ₹11,537.8 crore, compared to ₹ 10,588 crore in FY24. However, net profit for the year declined marginally by 0.9 per cent to ₹1,013.3 crore from ₹1,022.5 crore. The generics business, which includes active pharmaceutical ingredients (APIs) and generic formulations, posted a 46 per cent YoY revenue increase to ₹1,048 crore. Syngene, Biocon's research arm, recorded an 11 per cent growth in revenue to ₹1,018 crore. Biocon Biologics, the company's biosimilars segment, reported 9 per cent revenue growth to ₹2,463 crore. 'The launch of Liraglutide in the UK marked our entry into the GLP-1 therapy segment. Our biosimilars continue to build global market share, with four biosimilars generating over $200 million in FY25. This quarter also saw Syngene expand its biologics manufacturing footprint through the acquisition of a US facility,' said Kiran Mazumdar-Shaw, Chairperson, Biocon Group. Siddharth Mittal, CEO and Managing Director of Biocon, attributed the generics division's growth to new launches such as Lenalidomide and Dasatinib in the US, supported by moderate growth in APIs. 'We are focused on strategically expanding our differentiated GLP-1 portfolio into new markets, positioning us for long-term growth. We also expect a recovery in the API business in FY26, aided by cost improvements, operational efficiencies, and new capacity additions,' he said. Shreehas Tambe, CEO and Managing Director of Biocon Biologics, said performance was driven by market share gains in the US and key tender wins in emerging markets. 'We are well positioned to launch five new products in the next 12–18 months and expand patient access,' he added. Peter Bains, CEO and Managing Director of Syngene International, noted that Q4 revenue grew 11 per cent YoY and 8 per cent sequentially, crossing ₹1,000 crore in quarterly revenue for the first time. 'While global market dynamics remain uncertain, the positive momentum that drove Syngene's growth in the latter half of FY25 is expected to continue into FY26,' he said. The Board has recommended a final dividend of ₹0.50 per share (10 per cent of face value) for the financial year ended 31 March 2025. Biocon also secured 12 regulatory approvals and made several filings for biosimilars including bUstekinumab, bDenosumab, and bAflibercept across multiple countries, aiming to expand patient access globally. The Q4 results were announced after market hours. Biocon shares closed 3 per cent lower at ₹334.60 apiece on Thursday.
Business Upturn
08-05-2025
- Business
- Business Upturn
Biocon Q4FY25 results: Net profit jumps 153% YoY to Rs 344 crore; revenue rises 12% to Rs 4,454 crore
By News Desk Published on May 8, 2025, 19:50 IST Biocon Limited reported a strong financial performance for the quarter and financial year ended March 31, 2025. For Q4FY25, consolidated revenue came in at Rs 4,454 crore, marking a 12% year-on-year (YoY) increase. On a like-for-like basis, the revenue grew 15% YoY after adjusting for revenues from Branded Formulations India (BFI). EBITDA rose 16% YoY to Rs 1,115 crore with an EBITDA margin of 25%. Core EBITDA, excluding R&D and other adjustments, came in at Rs 1,363 crore with a margin of 31%. The company posted a net profit of Rs 344 crore in Q4FY25, a significant 153% YoY jump. On a like-for-like basis, the net profit rose 162% YoY. Profit before tax (PBT) surged 53% YoY to Rs 487 crore. Segmental performance Generics : Revenue rose 46% YoY to Rs 1,048 crore, driven by strong contributions from Lenalidomide and Dasatinib launches in the U.S. : Revenue rose 46% YoY to Rs 1,048 crore, driven by strong contributions from Lenalidomide and Dasatinib launches in the U.S. Biosimilars : Revenue increased 4% YoY to Rs 2,463 crore. On an adjusted basis, it rose 9% YoY. : Revenue increased 4% YoY to Rs 2,463 crore. On an adjusted basis, it rose 9% YoY. Research Services (Syngene): Revenue climbed 11% YoY to Rs 1,018 crore. Full-year FY25 highlights For the full year, Biocon reported: Total revenue : Rs 16,470 crore, up 5% YoY (8% like-for-like) : Rs 16,470 crore, up 5% YoY (8% like-for-like) EBITDA : Rs 4,374 crore, up 5% YoY : Rs 4,374 crore, up 5% YoY Net profit: Rs 1,013 crore, down 1% YoY; however, like-for-like net profit increased 30% Dividend and capital plans The Board recommended a final dividend of Rs 0.50 per share. Additionally, it approved raising up to Rs 4,500 crore through various financial instruments for debt repayment and strategic investments. Strategic developments Biocon Biologics launched its fifth biosimilar, Yesintek (bUstekinumab), in the U.S. and Germany, and secured a U.S. market entry for Yesafili (bAflibercept). The company also partnered with Civica Inc. to increase access to insulins. Syngene crossed Rs 1,000 crore in quarterly revenue for the first time and acquired a biologics manufacturing facility in the U.S., expanding its CDMO capabilities. Biocon has also initiated an evaluation of a potential merger between Biocon Limited and Biocon Biologics. Sustainability Biocon and Biocon Biologics were both included in the S&P Global Sustainability Yearbook 2025, with Biocon ranked among the top 5% in the Biotechnology sector. News desk at
Time of India
23-04-2025
- Business
- Time of India
Aurobindo Pharma arm gets USFDA nod for generic blood cancer drug
Aurobindo Pharma on Wednesday said its wholly- owned arm Eugia Pharma Specialities Ltd has received final approval from the USFDA to manufacture and market its generic version of Dasatinib tablets indicated in certain types of cancer of bone marrow and blood. The approval by the US Food & Drug Administration (USFDA) is for manufacturing and marketing of Dasatinib tablets of strengths 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Aurobindo Pharma said in a regulatory filing. These are bioequivalent and therapeutically equivalent to the reference listed drug Sprycel Tablets in the same strengths, of Bristol-Myers Squibb Company (BMS), it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like If You Eat Ginger Everyday for 1 Month This is What Happens Tips and Tricks Undo The product is expected to be launched in Q1FY26, Aurobindo Pharma said. The approved product has an estimated market size of USD 1.8 billion for the 12 months ended February 2025, it said citing IQVIA MAT data.
&w=3840&q=100)
Business Standard
23-04-2025
- Business
- Business Standard
Aurobindo Pharma in focus: Why has the stock gained 3% in trade today?
Aurobindo Pharma Ltd share price: Shares of Aurobindo Pharma gained 2.9 per cent in trade, registering an intraday high at ₹1,222.9 on the BSE. The up move in the stock came after the company arm Eugia Pharma Specialities, received final approval from the US Food & Drug Administration (US FDA) to manufacture and market Dasatinib tablets. According to the filing, Dasatinib tablets are indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib and adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy. At 12:22 PM, Aurobindo Pharma shares were trading 2.65 per cent higher at ₹1,219.6 per share on the BSE. In comparison, the BSE Sensex was up 0.20 per cent at 79,757.46. The market capitalisation of the company stood at ₹70,834.57 crore. The 52-week high of the stock was at ₹1,592.55 per share and 52-week low of the stock was at ₹994.35 per share. Eugia Pharma will be manufacturing Dasatinib Tablets of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, of Bristol-Myers Squibb Company (BMS). The product is expected to be launched in Q1FY26. The approved product has an estimated market size of $1.8 billion for the twelve months ending February 2025, according to IQVIA MAT. This is the 181st ANDA approval (including 9 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products. ALSO READ | Bharti Hexacom hits all time high after 400 MHz deal with with Adani firm About Aurobindo Pharma Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercialises a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 30+ manufacturing and packaging facilities. Its robust product portfolio is spread over seven major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and AntiAllergic, supported by a strong R&D set-up.
